Clinical trial
GMB: Study of Truvada (TDF+FTC) or Emtricitabine (FTC) Alone Versus HAART…
NCT00362687 · Gilead Sciences, Industry · Completed
Key facts
| NCT number | NCT00362687 |
|---|---|
| Title | GMB: Study of Truvada (TDF+FTC) or Emtricitabine (FTC) Alone Versus HAART Interruption in HIV-Infected Patients With Resistance |
| Official title | GMB: Phase IV, Multicenter, Randomized, Open-Label Pilot Study of Truvada (TDF+FTC) or Emtricitabine (FTC) Alone Versus HAART Interruption in HIV-Infected Patients Who Need to Interrupt HAART and Who Are Infected With HIV Isolates Containing at Least 2 TAMs (or K65R) and M184V |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug, Procedure |
| Interventions | Truvada (TDF+FTC) alone, FTC alone, No HAART |
| Enrollment | 50 |
| Start date | Nov 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Aug 10, 2006 |
| Last update posted | Mar 31, 2009 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: